C-7H02autophagy activation, phenotypic screening, iPSCs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Discover and develop therapeutics for age-related neurodegenerative diseases by activating autophagy.
Phenotypic screening platform using patient-derived iPSCs; autophagy activation biology.
Platform supports a portfolio including ALS, Parkinson's Disease, and Charcot-Marie-Tooth Disease programs; company raised a $25M Series A in 2021 led by Apollo Health Ventures.
Develop an autophagy-activating therapeutic program within Samsara Therapeutics' neurodegenerative disease portfolio.
Drug discovery/development using Samsara's autophagy activation and patient-derived iPSC phenotypic screening approach.
Listed in company pipeline.
Develop an autophagy-activating therapeutic program within Samsara Therapeutics' neurodegenerative disease portfolio.
Drug discovery/development using Samsara's autophagy activation and patient-derived iPSC phenotypic screening approach.
Listed in company pipeline.
Develop an autophagy-activating therapeutic program within Samsara Therapeutics' neurodegenerative disease portfolio.
Drug discovery/development using Samsara's autophagy activation and patient-derived iPSC phenotypic screening approach.
Listed in company pipeline.
Develop an autophagy-activating therapeutic program within Samsara Therapeutics' neurodegenerative disease portfolio.
Drug discovery/development using Samsara's autophagy activation and patient-derived iPSC phenotypic screening approach.
Listed in company pipeline.